Generate Biomedicines, Inc. Common Stock (GENB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Generate Biomedicines, Inc. Common Stock stock (GENB) is currently trading at $11.81. Generate Biomedicines, Inc. Common Stock PS ratio (Price-to-Sales) is 37.88. WallStSmart rates GENB as Sell.
- GENB PE ratio analysis and historical PE chart
- GENB PS ratio (Price-to-Sales) history and trend
- GENB intrinsic value — DCF, Graham Number, EPV models
- GENB stock price prediction 2025 2026 2027 2028 2029 2030
- GENB fair value vs current price
- GENB insider transactions and insider buying
- Is GENB undervalued or overvalued?
- Generate Biomedicines, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- GENB Piotroski F-Score and Altman Z-Score
- GENB analyst price target and Smart Rating
Generate Biomedicines, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Generate Biomedicines, Inc. Common Stock (GENB) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around price/sales and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Generate Biomedicines, Inc. Common Stock (GENB) Key Strengths (0)
Generate Biomedicines, Inc. Common Stock (GENB) Areas to Watch (3)
Very expensive at 37.9x annual revenue
Very low institutional interest at 0.00%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Generate Biomedicines, Inc. Common Stock (GENB) Detailed Analysis Report
Overall Assessment
This company scores 8/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Price/Sales, Institutional Own., Market Cap. Some valuation metrics including Price/Sales (37.88) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 1:20:03 PM
About Generate Biomedicines, Inc. Common Stock(GENB)
NASDAQ
NONE
NONE
USA
None